Evaluation of the diagnostic quality of manganese chloride tetrahydrate (CMC-001©) in liver magnetic resonance imaging in patients with liver metastases in comparison to gadolinium benzyloxypropionictetraacetate (BOPTA): a randomised cross-over phase III trial

Study hypothesis: The primary objective is to assess the feasibility of manganese chloride tetrahydrate (CMC-001©) as a contrast medium in liver Magnetic Resonance Imaging (MRI) scanning in patients with liver metastases in comparison with gadolinium Benzyloxypropionictetraacetate (BOPTA) (MultiHance©) MRI.
Primary outcome(s): The primary objective is to assess the feasibility of CMC-001© as a contrast medium in liver MRI scanning in patients with liver metastases in comparison with gadolinium BOPTA (MultiHance©) MRI.